Anna Moszczynska
Overview
Explore the profile of Anna Moszczynska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chauhan H, Carruthers N, Stemmer P, Schneider B, Moszczynska A
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684782
In recent years, methamphetamine (METH) misuse in the US has been rapidly increasing, and there is no FDA-approved pharmacotherapy for METH use disorder (MUD). In addition to being dependent on...
2.
Chauhan H, Carruthers N, Stemmer P, Schneider B, Moszczynska A
bioRxiv
. 2024 Aug;
PMID: 39091864
In recent years, methamphetamine METH misuse in the US has been rapidly increasing and there is no FDA-approved pharmacotherapy for METH use disorder (MUD). In addition to being dependent on...
3.
Miao B, Xing X, Bazylianska V, Madden P, Moszczynska A, Zhang B
Commun Biol
. 2023 Sep;
6(1):991.
PMID: 37758941
Psychostimulant methamphetamine (METH) is neurotoxic to the brain and, therefore, its misuse leads to neurological and psychiatric disorders. The gene regulatory network (GRN) response to neurotoxic METH binge remains unclear...
4.
Bazylianska V, Sharma A, Chauhan H, Schneider B, Moszczynska A
Int J Mol Sci
. 2022 Jan;
23(1).
PMID: 35008791
Methamphetamine (METH) is a highly abused psychostimulant that is neurotoxic to dopaminergic (DAergic) nerve terminals in the striatum and increases the risk of developing Parkinson's disease (PD). In vivo, METH-mediated...
5.
Moszczynska A
Curr Neuropharmacol
. 2021 Dec;
19(12):2058-2059.
PMID: 34911414
No abstract available.
6.
Moszczynska A
Curr Neuropharmacol
. 2021 Aug;
19(12):2077-2091.
PMID: 34344291
Almost two decades have passed since the last methamphetamine (METH) abuse epidemic. In recent years, METH abuse in the United States has been rapidly increasing and is currently one of...
7.
Sharma A, Bazylianska V, Moszczynska A
Exp Neurol
. 2021 Jul;
345:113811.
PMID: 34298012
Methamphetamine (METH) is a highly addictive and powerful central nervous system psychostimulant with no FDA-approved pharmacotherapy. Parkin is a neuroprotective protein and its loss of function contributes to Parkinson's disease....
8.
Sharma A, Harutyunyan A, Schneider B, Moszczynska A
Transl Psychiatry
. 2021 May;
11(1):293.
PMID: 34001858
There is no FDA-approved medication for methamphetamine (METH) use disorder. New therapeutic approaches are needed, especially for people who use METH heavily and are at high risk for overdose. This...
9.
Gontarz P, Fu S, Xing X, Liu S, Miao B, Bazylianska V, et al.
Sci Rep
. 2020 Jun;
10(1):10150.
PMID: 32576878
ATAC-seq is widely used to measure chromatin accessibility and identify open chromatin regions (OCRs). OCRs usually indicate active regulatory elements in the genome and are directly associated with the gene...
10.
Moszczynska A
Genes (Basel)
. 2020 Apr;
11(4).
PMID: 32231019
Methamphetamine (METH) is a widely abused psychostimulant with the potential to cause a broad range of severe cognitive deficits as well as neurobehavioral abnormalities when abused chronically, particularly at high...